Related Experiment Videos
[Comparative study of 3 different prophylactic programs in hemophiliac children]
Insights
Continuous prophylaxis is effective for hemophilic children when started early, improving quality of life. Therapeutic prophylaxis is better tolerated for target joint stabilization, despite higher costs.
Area of Science:
- Pediatric Hematology
- Hemophilia Management
- Prophylactic Therapy
Background:
- Prophylaxis is a key discussion point in pediatric hemophilia therapy.
- Standardized parameters for evaluating prophylactic treatment efficacy are lacking.
- Hemophilia management requires effective strategies to prevent bleeding and joint damage.
Purpose of the Study:
- To evaluate the efficacy of three different prophylactic programs in children with hemophilia.
- To compare outcomes before and after the implementation of prophylactic regimens.
- To assess the impact of early intervention and therapeutic prophylaxis on joint health and quality of life.
Main Methods:
- Implementation of three distinct prophylactic programs in 52 children aged 12 months to 14 years 7 months.
- Comparative analysis of clinical data from the 12 months preceding and following program initiation.
- Evaluation of treatment acceptance by children and parents.
Main Results:
- Continuous prophylaxis demonstrated significant efficacy when initiated early, prior to arthropathy development.
- Therapeutic prophylaxis was more readily accepted for stabilizing target joints.
- Improved quality of life was observed in patients undergoing prophylactic programs.
Conclusions:
- Early initiation of continuous prophylaxis is crucial for effective hemophilia management in children.
- Therapeutic prophylaxis offers a well-accepted alternative for specific joint issues.
- The benefits of prophylactic programs, including enhanced quality of life, justify their associated costs.
Abstract:
Prophylaxis continues to be an area for discussion in the therapy of the hemophilic child. In fact, standard parameters are still not used in the evaluation of the efficacy of this treatment. At the Milan University Pediatric Clinic we have begun three different prophylactic programs with 52 children with ages ranging from 12 months to 14 years 7 months. We have evaluated the efficacy of these regimes comparing the data obtained in the 12 months following the start of the program with those obtained in the 12 months prior to it. Our data, even though they pertain to a limited number of children, show that continuous prophylaxis is truly efficacious if it is begun early before the onset of an arthopathy. Therapeutic prophylaxis however for the stabilizing of a target joint is usually better accepted by the children and their parents. The high cost of the prophylactic programs can nevertheless be justified by the better quality of life of the patients.